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OBJECTIVE
To explore gallbladder- and biliary tract–related events reported for the liraglutide
and placebo groups in the Liraglutide Effect and Action in Diabetes: Evaluation
of Cardiovascular Outcome Results (LEADER) trial.
RESEARCH DESIGN AND METHODS
LEADER was an international, randomized, double-blind, controlled cardiovascular
(CV) outcomes trial. Participants with type 2 diabetes at high risk for CV events (n =
9,340) were randomized 1:1 to receive either liraglutide (£1.8 mg daily; n = 4,668) or
placebo (n = 4,672), with both groups also receiving standard care (treatment
period: 3.5–5 years). Acute gallstone disease was a medical event of special interest.
This post hoc analysis categorized captured events of acute gallbladder or biliary
disease into four groups: uncomplicated gallbladder stones, complicated gallblad-
der stones, cholecystitis, and biliary obstruction. Time to first event by treatment
group was analyzed using Cox regression.
RESULTS
There was an increased risk of acute gallbladder or biliary disease with liraglutide
versus placebo (n = 141 of 4,668 vs. n = 88 of 4,672 patients, respectively; hazard ratio
[HR] 1.60; 95% CI 1.23, 2.09; P < 0.001). Similar trends were observed for each of the
four categories of gallbladder- or biliary tract–related events. Cholecystectomy
was performed more frequently in liraglutide-treated patients (HR 1.56; 95% CI
1.10, 2.20; P = 0.013) but for similar proportions of the patients who experi-
enced gallbladder- or biliary tract–related events (57% with liraglutide vs. 59%
with placebo).
CONCLUSIONS
Although LEADER was not specifically designed to assess acute gallbladder or biliary
disease, the trial showed an increased risk of gallbladder- or biliary tract–related
events with liraglutide versus placebo, which appeared to be consistent across
four categories of these events. Further studies should investigate the relevant
mechanisms.
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Patients with type 2 diabetes are at
approximately twofold greater risk of
biliary disease than those without di-
abetes (1). Research into the mecha-
nisms underlying gallstone disease is
ongoing, but these mechanisms are
thought to be linked to insulin resistance,
obesity, the metabolic syndrome, and
type 2 diabetes (2).
Treatment of type 2 diabetes with
glucagon-like peptide 1 receptor agonists
(GLP-1RAs) has also been associated with
increased risk of gallbladder events in
clinical trials, including higher rates of
cholelithiasis, versus comparators (3–5).
Possible heterogeneity in the risk of
gallbladder events across the GLP-1RA
class is reflected by the current medica-
tion labels, which do not include these
events as adverse drug reactions for all
GLP-1RAs (6,7). Cholelithiasis is a fre-
quently observed side effect of weight-
lowering therapies (8). For example, in
people with obesity, the prevalence of
new gallstones can exceed 10% after 8–
16 weeks of a low-calorie diet and exceed
30% after gastric bypass surgery (8). Use
of GLP-1RAs for the treatment of type 2
diabetes is associated with weight loss
(9,10). Therefore, weight loss should not
be disregarded when considering findings
of increased gallbladder-related adverse
events (AEs) (11). However, other mech-
anisms may be involved (4,11). For ex-
ample, it has also been suggested that
GLP-1RAs may have an inhibitory effect
on gallbladder motility (4,12).
A higher incidence of gallbladder-
related AEs was reported with liraglutide
3.0 mg versus placebo in the clinical de-
velopment program of this GLP-1RA for
weight management (13–15), although
no imbalances in gallbladder-related AEs
were observed between liraglutide 1.8 mg
and comparators in the type 2 diabetes
clinical development program (16–22).
The Liraglutide Effect and Action in
Diabetes: Evaluation of Cardiovascular
Outcome Results (LEADER) cardiovascu-
lar (CV) outcomes trial (CVOT) of liraglu-
tide included patients with type 2
diabetes at high CV risk (23). The trial
showed significantly decreased risks of
the primary composite major adverse
CV events outcome (time to first occur-
rence of CV death, nonfatal myocardial
infarction, or nonfatal stroke), CV death,
and all-cause death with liraglutide ver-
sus placebo (23). Rates of nonfatal myo-
cardial infarction, nonfatal stroke, and
hospitalization for heart failure were
nonsignificantly lower with liraglutide
versus placebo, while coronary re-
vascularization and hospitalization for
unstable angina pectoris were each ex-
perienced by similar proportions of pa-
tients in the two treatment groups (23).
Liraglutide was associated with signifi-
cant reductions from baseline in glycated
hemoglobin, weight, and systolic blood
pressure versus placebo and an increase
in diastolic blood pressure and heart rate
at 36 months (23).
In LEADER, the proportion of patients
with acute gallstone disease was higher
with liraglutide than with placebo (in
145 [3.1%] and 90 [1.9%] patients, re-
spectively; P , 0.001) (23). This finding
was driven by greater proportions of
patients experiencing cholelithiasis (68
patients [1.5%] vs. 50 [1.1%]) and acute
cholecystitis (36 patients [0.8%] vs.
21 [0.4%]) with liraglutide compared
with placebo (23). However, to date, data
regarding the subtypes of gallstone dis-
ease observed, and their implications
(e.g., cholecystectomy), have not been
fully described.
The aim of the present post hoc anal-
ysis was to explore the clinical features
of gallbladder- and biliary tract–related
events reported for the liraglutide and
placebo groups in LEADER. We also ex-
amined the relationship among liraglu-
tide, the risk of gallbladder- or biliary
tract–related events, and body weight
loss.
RESEARCH DESIGN AND METHODS
Study Design and Oversight
Methods relating to the LEADER trial,
including the trial protocol, have pre-
viously been published (23,24). Briefly,
410 sites from 32 countries participated
in this randomized, double-blind, pla-
cebo-controlled trial. The trial included
patients with type 2 diabetes at high risk
for CV events (aged$50 years with either
established CV disease or chronic kidney
disease or aged $60 years with $1 CV
risk factor). Participants were random-
ized 1:1 to receive either 1.8 mg s.c.
liraglutide daily (or maximum tolerated
dose of 0.6–1.8 mg daily) or matching
placebodboth in addition to standard-
of-care therapy. The treatment period
was 3.5–5 years, with a 30-day follow-up
period. The primary outcome was time
to first occurrence of CV death, nonfatal
(including silent) myocardial infarction,
or nonfatal stroke. The trial was approved
by institutional review boards, and all
patients provided written informed con-
sent (23).
A selective approach to safety data
collection was used (25), and only events
meeting the definition of a serious AE or
medical event of special interest (MESI)
were systematically collected and re-
ported. Acute gallstone disease, defined
as biliary colic or acute cholecystitis,
was prespecified as a MESI. These events,
both serious and nonserious, were re-
quired to be reported. As with other
prespecified MESIs, information related
to acute gallstone disease events was
collected using a designated form. Events
were captured for analysis based on
prespecified standard search terms from
the Medical Dictionary for Regulatory Ac-
tivities (MedDRA), version 18.0 (standard
MedDRA queries [SMQs]): functional, in-
flammatory, and gallstone-related biliary
disorders (SMQ); infectious biliary disor-
ders (SMQ).
In this post hoc analysis, baseline
characteristics of patients with events
of acute gallbladder or biliary disease
were evaluated. A blinded post hoc
review, performed by the sponsor
and first author, grouped the events
of acute gallbladder or biliary disease
by nature and severity into more clini-
cally meaningful categories. This review
included assessment of clinical features;
imaging findings of cholecystitis, chole-
lithiasis, or bile duct stones; pain; clinical
signs of cholestasis; interventions in-
cluding cholecystectomy or endoscopic
retrograde cholangiopancreatography
(ERCP); hospitalizations; fever; treat-
ment with antibiotics; and reason for
investigation. Events were classified
into four categories: uncomplicated
gallbladder stones, complicated gallblad-
der stones, cholecystitis with/without/
unknown gallstones, and biliary obstruc-
tion (Table 1).
Events for which sufficient information
was reported were classified using an
algorithm (as defined in Table 1). Events
with insufficient information for algorithm-
based classification were further re-
viewed and classified manually by the
sponsor and first author into the four
categories based on all available data
and clinical assessment of the event as
a whole. This analysis mainly relied on
the clinical diagnoses provided by the
investigators, even if there was limited
additive information. Events catego-
rized by this review were termed
“non–algorithm-based events.”
Analyses were performed using the
pooled categorized events (both algorithm-
based and non–algorithm-based events).
Events captured by the MedDRA search
but found during case review to be un-
related to biliary disease were excluded
from subsequent analyses. It should be
noted that a single patient could have
had several events during the trial and
therefore could be represented in dif-
ferent categories.
Body weight was ascertained at base-
line, 6 and 12months after randomization,
and then every 12 months until end of
treatment.
Statistical Analyses
Time to first event by treatment (liraglu-
tide vs. placebo) was analyzed using Cox
regression analysis, with treatment as a
fixed factor, and visualized using Kaplan-
Meier curves. Separate analyses were
conducted for each of the gallbladder-
or biliary tract–related event categories.
Patients without an event of interest
were censored at time of death or time
of last follow-up. No adjustment for mul-
tiple testing was performed.
Additional analyses were performed
that explored the relationship among
treatment, the risk of gallbladder- or biliary
tract–related events, and body weight loss.
The additional time-dependent analyses
used Cox regression, with treatment as a
fixed factor and change from baseline in
body weight as a time-dependent cova-
riate, adjusted for bodyweight at baseline.
Change in body weight was calculated for
each applicable visit that was prior to an
event or censoring.
Data and Resource Availability
The subject-level analysis data sets for
the research presented in this article are
available from the corresponding author
upon reasonable request.
RESULTS
In LEADER, 9,340 patients were random-
ized to either liraglutide (n = 4,668) or
placebo (n = 4,672) and followed for a
median of 3.8 years. The disposition of
trial participants has previously been
published (23).
A schematicoverviewof the reviewand
categorization of gallbladder- and biliary
tract–related events is available in
Supplementary Fig. 1. In total, 275 events
were identified in 235 patients. Seven
events were excluded from the analyses
after review, as these were assessed to be
unrelated tobiliary disease (Supplementary
Fig. 1 and Supplementary Table 1). Of the
remaining 268 events, 201 events in 181
patients were identified by the algorithm-
based classification and 67 events in 52
patients by the non–algorithm-based clas-
sification (Supplementary Fig. 1). For the
purposes of these analyses, we focused
on the pooled algorithm-based and
non–algorithm-based events, since
algorithm-based and clinical diagnosis–
related classification led to broadly
similar proportions for each cate-
gory (Supplementary Fig. 1). Categories
of gallbladder and biliary disease by
algorithm-based and non–algorithm-
based events are shown in Supplementary
Table 2.
In this exploratory, post hoc analysis,
there was an increased risk of gallbladder-
or biliary tract–related events with
liraglutide versus placebo (n = 141 vs.
n = 88 patients, respectively; hazard ratio
[HR] 1.60; 95% CI 1.23, 2.09; P , 0.001)
(Fig. 1A). Baseline characteristics of the
229 patients with gallbladder- or biliary
tract–related events were similar be-
tween the treatment groups and com-
parable with the total study population
(Table 2). Among patients with gallbladder-
or biliary tract–related events, fewer in
the liraglutide group had a history of
cholecystitis at screening than in the
placebo group, but this observation was
based on low patient numbers (Table 2).
More patients treated with liraglutide
than those treated with placebo had
uncomplicated gallbladder stones (n =
16 and n = 5 for liraglutide and pla-
cebo), complicated gallbladder stones
(n = 52 and n = 40), cholecystitis (n =
51andn= 33), andbiliary obstruction (n=
25 and n = 16) (Table 3 and Fig. 1B–E).
In separate evaluations as algorithm-
based and non–algorithm-based events,
a similar pattern of results (more events
with liraglutide across most catego-
ries) was observed (Supplementary
Table 2).
Cholecystectomy was more common
in patients treated with liraglutide ver-
sus placebo (n = 81 [1.74%] and n =
52 [1.11%], respectively; HR 1.56; 95%
CI 1.10, 2.20;P=0.013).However, among
patients who had a gallbladder- or biliary
tract–related event during the trial, the
proportion undergoing cholecystectomy
was similar with liraglutide versus pla-
cebo: 57% vs. 59% (n = 81 of 141 patients
Table 1—Categorization of events according to the algorithm
Category Criteria
Uncomplicated gallbladder stones - Eventswith imaging results supportiveof gallbladder stonesandnot supportiveof cholecystitis
or bile duct stones.
- Absence of pain or clinical signs of cholestasis.
- Event not leading to cholecystectomy or ERCP at a later stage.
Complicated gallbladder stones - Eventswith imaging results suggestiveof gallbladder stones andnot supportiveof cholecystitis
or bile duct stones AND
- Presence of typical pain AND/OR leading to cholecystectomy or ERCP.
Cholecystitis with/without gallbladder stones - Events with imaging results suggestive of cholecystitis AND not supportive of bile duct stones.
- Presence of typical pain AND/OR leading to cholecystectomy or ERCP.
Biliary obstruction - Events with imaging results suggestive of bile duct stones.
Additional clinical review In addition to the above strict criteria, events grouped as “complicated gallbladder stones” and
that had copresence of either fever and/or clinical signs of cholestasis were reviewed and
potentially regrouped. Events with presence of clinical signs of cholestasis but with imaging
results showing no presence of bile duct stones were reviewed and grouped into one of the
four categories.
Figure 1—Time to first gallbladder or biliary disease event in patients from all four gallbladder- or biliary tract–related event categories (A), patients
with uncomplicated gallbladder stones (B), patients with complicated gallbladder stones (C), patients with cholecystitis (D), and patients with
biliary obstruction (E). The two-sided P values are from the testing of the hypothesis of no difference between treatments. The parameter has been
analyzed using a Cox regression model with treatment as a fixed factor. No adjustment for multiple testing was performed. The x-axes are truncated
at 42 months because a smaller number of patients had an observation time beyond the minimum treatment period of 42 months.
who experienced gallbladder- or biliary
tract–related events in the liraglutide
group vs. n = 52 of 88 patients who
experienced gallbladder- or biliary
tract–related events in the placebo
group).
The average weight loss in the trial
was greater in patients experiencing a
gallbladder- or biliary tract–related event
with liraglutide (25.3 kg) or placebo
(23.3 kg) compared with those patients
not experiencing an event (23.0 kg and
20.6 kg for liraglutide and placebo,
respectively) (Table 2). Additional ex-
ploratory analyses, using Cox regression
adjusted for body weight at baseline, with
change in body weight as a time-dependent
covariate and assuming a crude linear
relationship with risk of gallbladder- or
biliary tract–related events, showed a
slightly attenuated effect of liraglutide
versus placebo on the risk of a gallbladder-
or biliary tract–related event (HR 1.47;
95% CI 1.12, 1.92) compared with the
main analysis (HR 1.60; 95% CI 1.23,
2.09). Qualitatively similar results were
obtained from a mediation analysis as-
sessing the role of weight loss in
gallbladder events with liraglutide treat-
ment (data not shown). The time-
dependent Cox regression analyses also
indicated that a weight loss of 1 kg during
the trial was associated with an ;4%
increase of the risk of a gallbladder- or
biliary tract–related event.
CONCLUSIONS
In LEADER, the overall risk of acute
gallstone disease was increased with
liraglutide versus placebo (23). In this
post hoc analysis of LEADER data, which
explored gallbladder- and biliary tract–
related events after clinical review, the
increase in the overall risk of gallbladder-
or biliary tract–related events remained
(Fig. 1A). The observation appeared to
be consistent across the four categories
of gallbladder- or biliary tract–related
events (uncomplicated gallbladder stones,
complicated gallbladder stones, cholecys-
titis with/without gallbladder stones, and
biliary obstruction).
From a clinical perspective, the sever-
ity and implications of the gallbladder-
and biliary tract–related events (e.g.,
cholecystectomy) are of interest. The
four categories of gallbladder- and biliary
tract–related events used in this analysis
represent, to some extent, different se-
verities across the spectrum of gallblad-
der- and biliary tract–related diseases.
The estimated effect sizes (HRs) for the
different categories of gallbladder- or
biliary tract–related events all showed
an imbalance with liraglutide versus pla-
cebo, favoring placebo. We also showed
that cholecystectomy was performed
more frequently for liraglutide-treated
than placebo-treated patients but for
similar proportions of patients who ex-
perienced gallbladder- or biliary tract–
related events during the trial. The latter,
nonrandomized comparison suggests
that gallbladder- and biliary tract–related
events may have had similar severity
and implications with liraglutide and
placebo, on average, based on the rel-
ative need for cholecystectomy. How-
ever, this comparison should be
interpreted with caution, as patients
who experienced gallbladder- or biliary
tract–related events in the liraglutide or
placebo groups may not have been com-
parable across these treatment groups. It
Table 2—Demographics at baseline or screening and clinical characteristics
Patients with gallbladder- or biliary
tract–related events












n 141 88 4,527 4,584 9,340
Age (years) 65.4 (7.9) 65.0 (7.4) 64.2 (7.2) 64.4 (7.2) 64.3 (7.2)
Male, n (%) 86 (61.0) 53 (60.2) 2,925 (64.6) 2,939 (64.1) 6,003 (64.3)
BMI (kg/m2) 32.8 (5.9) 32.9 (6.9) 32.5 (6.3) 32.5 (6.3) 32.5 (6.3)
Weight (kg) 93.2 (21.1) 90.9 (22.1) 91.9 (21.2) 91.6 (20.7) 91.7 (21.0)
HbA1c (%) 8.6 (1.5) 9.0 (1.7) 8.7 (1.6) 8.7 (1.5) 8.7 (1.5)
HbA1c (mmol/mol) 70.3 (16.2) 75.1 (18.3) 72.0 (17.0) 71.0 (16.3) 71.5 (16.7)
Diabetes duration (years) 12.8 (8.3) 12.0 (7.7) 12.8 (7.9) 12.9 (8.1) 12.8 (8.0)
Pancreatitis and gallbladder history, n (%)
Pancreatitis 5 (3.5) 5 (5.7) 141 (3.1) 113 (2.5) 264 (2.8)
Gallstone disease 20 (14.2) 14 (15.9) 549 (12.1) 520 (11.3) 1,103 (11.8)
Cholecystitis 4 (2.8) 11 (12.5) 339 (7.5) 313 (6.8) 667 (7.1)
Lipids (mmol/L)
HDL cholesterol 1.2 (0.3) 1.1 (0.3) 1.2 (0.3) 1.2 (0.3) 1.2 (0.3)
LDL cholesterol 2.4 (0.9) 2.4 (1.0) 2.3 (0.9) 2.3 (0.9) 2.3 (0.9)
Total cholesterol 4.5 (1.2) 4.5 (1.1) 4.4 (1.2) 4.4 (1.2) 4.4 (1.2)
Triglycerides 2.1 (1.3) 2.4 (2.6) 2.1 (1.5) 2.0 (1.7) 2.1 (1.6)
Biochemistry
Total bilirubin (mmol/L) 7.9 (4.5) 7.8 (4.1) 7.8 (4.1) 7.8 (4.3) 7.8 (4.2)
ALT (units/L) 25.9 (14.7) 25.9 (15.4) 27.0 (16.6) 26.5 (15.7) 26.8 (16.1)
Weight change from baseline at end of
treatment (kg) 25.3 (10.1) 23.3 (8.8) 23.0 (7.1) 20.6 (6.6) d
Values are mean (SD) unless otherwise stated. Pancreatitis and gallbladder history data were obtained at screening. ALT, alanine aminotransferase;
HbA1c, glycated hemoglobin; n, number of patients.
should also be noted that cholecystectomy
was more common in patients treated
with liraglutide versus placebo overall,
probably because more gallbladder- and
biliary tract–related events occurred in
liraglutide-treated individuals. These results
are consistent with findings from a trial
of liraglutide 3.0 mg conducted in people
without type 2 diabetes, in which more
gallbladder-related events were observed
in liraglutide-treatedparticipants compared
with placebo-treated participants, but
there were similar proportions of elective
cholecystectomies among those with
cholelithiasis or cholecystitis (15).
Gallbladder events are the most com-
mon cause of acute pancreatitis, account-
ing for ;45% of cases (26). While
numbers of relevant events were low,
the LEADER trial demonstrated that
fewer patients treated with liraglutide
experienced acute pancreatitis com-
pared with those treated with placebo
(n = 18 and n = 23 for liraglutide and
placebo, respectively) (23,27). This ob-
servation suggests that the increase in
gallbladder- and biliary tract–related
events observed with liraglutide versus
placebo did not result in an increased
occurrence of acute pancreatitis events
in the LEADER trial.
CVOTs of exenatide once weekly and
lixisenatide reported that more patients
experienced cholecystitis/cholelithiasis
events (n = 178 [2.4%] for exenatide
and n = 146 [2.0%] for placebo) or hep-
atobiliary serious AEs (n = 36 [1.2%] for
lixisenatide and n = 28 [0.9%] for placebo),
respectively, with GLP-1RA treatment
(28,29). Moreover, a numeric imbalance
in hepatobiliary disorders was observed
with albiglutide versus placebo in the
Harmony Outcomes trial (n = 51 patients
[1%] for albiglutide and n = 41 patients
[1%] for placebo; relative risk 1.24; 95%
CI 0.83, 1.87) (30). In the Trial to Evaluate
Cardiovascular and Other Long-term
Outcomes With Semaglutide in Subjects
With Type 2 Diabetes (SUSTAIN 6), a
CVOT with eligibility criteria similar to
those for LEADER, gallbladder disorders
occurred in similar numbers of patients
treated with subcutaneous semaglutide
and placebo (n = 58 vs. n = 61, respec-
tively) (31). Interestingly, this observa-
tion was made despite an overall higher
mean body weight loss with the active
drug relative to placebo in SUSTAIN 6
at 2 years (2.9 kg for 0.5 mg semaglutide
and 4.3 kg for 1.0 mg semaglutide)
(31) compared with LEADER at 3 years
(in which weight loss with liraglutide
relative to placebo was 2.3 kg) (23). The
relatively short duration of follow-up in
the SUSTAIN 6 trial (2.1 years) should be
noted, however (31). While no imbalance
in gallbladder disorders was observed
with semaglutide versus placebo, it re-
mains possible that an imbalance may
have emerged after a longer duration of
follow-up. Possible heterogeneity in the
relationship between gallbladder events
and different GLP-1RAs is reflected by
the current medication labels, which do
not list these events as adverse drug
reactions for all GLP-1RAs (6,7). How-
ever, more evidence is needed regarding
the relative effects of individual GLP-
1RAs on gallbladder events and the un-
derlying mechanisms.
The increased risk of gallbladder- and
biliary tract–related events reported in
the present post hoc analysis could po-
tentially be due to an investigation bias
related to the emergence of gastrointes-
tinal symptoms with liraglutide (based on
phase IIIa trials, nausea and diarrhea are
observed in $1 of 10 patients) (32). If
true, the increased risk would be ex-
pected to result from a greater number
of uncomplicated (asymptomatic) cases,
particularly early in the course of therapy
(2–4 months), when gastrointestinal AEs
are more common with liraglutide. A
greater number of uncomplicated events
was indeed observed with liraglutide,
and a between-group difference in the
proportion of patients with these events
emerged shortly after randomization
(Fig. 1B). However, these observations
were based on low numbers of patients
in both treatment groups. Furthermore,
the imbalance favoring placebo was not
confined to uncomplicated events but,
rather, was observed across all four
clinical categories of gallbladder- or biliary
tract–related events, and gallbladder
events accrued at a relatively constant
rate throughout the trial.
Weight loss in patients undergoing
low-calorie diets or gastric bypass sur-
gery is associated with an increased risk
of gallstones (8). GLP-1RA treatment is
also associated with weight loss (5,9).
Liraglutide 1.8 mg daily reduces energy
intake in patients with type 2 diabetes
versus placebo, without significantly al-
tering macronutrient distribution, which
may contribute to liraglutide-induced
weight loss (33). Rapid weight loss mo-
bilizes cholesterol from the liver and
adipose tissue, and in the short term,
Table 3—Categories of gallbladder or biliary disease complications (pooled
algorithm-based and non–algorithm-based events)








N % E N % E N % E
All events 141 3.02 155 88 1.88 113 229 2.45 268
Uncomplicated gallbladder stones 16 0.34 17 5 0.11 7 21 0.22 24
Complicated gallbladder stones 52 1.11 54 40 0.86 42 92 0.99 96
Leading to cholecystectomy 31 0.66 32 22 0.47 22 53 0.57 54
Cholecystitis 51 1.09 56 33 0.71 35 84 0.90 91
Without gallbladder stones 19 0.41 21 8 0.17 8 27 0.29 29
With gallbladder stones 30 0.64 33 22 0.47 24 52 0.56 57
Unknown stone status 2 0.04 2 3 0.06 3 5 0.05 5
Leading to cholecystectomy 39 0.84 43 26 0.56 28 65 0.70 71
Biliary obstruction 25 0.54 28 16 0.34 29 41 0.44 57
Bile duct stones 22 0.47 24 13 0.28 18 35 0.37 42
Bile duct stenosis 3 0.06 4 3 0.06 11 6 0.06 15
Intervention
ERCP 9 0.19 11 6 0.13 18 15 0.16 29
Papillotomy 4 0.09 5 6 0.13 10 10 0.11 15
Stenting (biliary prosthesis) 1 0.02 2 2 0.04 11 3 0.03 13
Cholecystectomy 12 0.26 13 8 0.17 9 20 0.21 22
Seven events and six patients were excluded, since the seven events were assessed to be unrelated
tobiliary disease. The sevenexcludedevents occurred in sevenpatients, but, as oneof thepatients
also had another gallbladder- or biliary tract–related event, this patient was included in the
analyses for the other event. For some patients, cholecystectomy was reported for two separate
events with the same start date. Therefore, more cholecystectomy events than patients with
cholecystectomy are listed for some categories of gallbladder or biliary disease. E, number of
events; n, number of patients; N, number of patients with an event; %, percentage of patients.
fasting increases the cholesterol satura-
tion of gallbladder bile (34). In the longer
term, fasting causes gallbladder stasis,
which can lead to sludge and gallstone
formation (34). Therefore, reduced en-
ergy intake and weight loss associated
with liraglutide could represent potential
mechanisms to explain, in part, the ef-
fects of liraglutide on gallbladder- or biliary
tract–related events (11,33). Other med-
ications associated with weight loss and
increased frequencies of gallbladder- or
biliary tract–related events versus pla-
cebo include orlistat (cholelithiasis: 2.9%
vs. 1.8% with placebo) and naltrexone/
bupropion (cholecystitis reported in
,2% of patients but with an incidence
at least twice that of placebo) (35,36).
However, this is not a uniform finding in
studies examining treatments associated
with weight loss. For example, weight
loss has been observedwith the sodium–
glucose cotransporter 2 inhibitor dapa-
gliflozin versus placebo, but serious AEs
of cholelithiasis and acute cholecystitis
were reported in similar proportions of
patients in the two treatment groups (37).
In the current analysis, we have shown
that patients with a gallbladder- or biliary
tract–related event experienced more
weight loss in the trial than those without
an event. However, the relationship
among GLP-1RA treatment, weight
loss, and gallbladder-related events is
not fully clear, as exemplified by differ-
ences in observations for subcutaneous
semaglutide in SUSTAIN 6 compared with
liraglutide in LEADER, as described above
(23,31). In one of the SCALE weight-
management trials for liraglutide 3.0
mg in individuals with overweight or
obesity and without type 2 diabetes, more
participants experienced gallbladder-
related events with liraglutide than with
placebo (n = 61 [2.5%] vs. n = 12
[1.0%], respectively), and weight loss
among these participants was higher
than the mean weight loss in the total
trial cohort (15). However, while the
majority of the weight loss was observed
during the first;40 weeks of treatment,
the incidence of gallbladder-related AEs
remained relatively constant over the full
160 weeks (14). The increased incidence
of gallbladder-related AEs with liraglu-
tide 3.0 mg could therefore be due to
both weight loss–dependent and weight
loss–independent effects. The results we
report in the current analysis, whereby
adjusting for baseline body weight and
change in body weight only slightly at-
tenuated the effect of liraglutide on
the risk of a gallbladder- or biliary
tract–related event, predominantly sup-
port weight-independent effects and
only to a smaller extent indicate weight-
dependent effects.
Another potential mechanism sug-
gested is an inhibitory effect on gallblad-
der motility (4,12). Impaired gallbladder
mobility can lead to sludge and gallstone
formation and has been described as a
contributing factor in the development
of gallstones with other medications,
e.g., the somatostatin analog octreotide
(34). GLP-1 infusion suppresses the se-
cretion of cholecystokinin after a meal,
which reduces gallbladder contractil-
ity (38). Exenatide, lixisenatide, and al-
biglutide have been shown to reduce
cholecystokinin-induced gallbladder ejec-
tion fraction, compared with placebo,
in healthy individuals (39–41). Liraglutide
has no effects on fasting gallbladder
volumes or the maximum postprandial
gallbladder ejection fraction but does
appear to delay the time to maximum
contraction of the gallbladder (12,42).
However, the clinical significance of
these findings is yet to be elucidated
(12). Differential effects of GLP-1RAs
on gallbladder motility have not been
examined.
Overall, the mechanism for the in-
creased occurrence of gallbladder stones
with liraglutide remains unclear, but it
may involve altered bile acid production
and secretion, decreased gallbladder
emptying, weight loss, or a combination
of all of these (5,43). A further, recently
proposed explanation for the gallbladder
events observed in GLP-1RA clinical trials
is GLP-1RA–induced prolongation of gall-
bladder refilling (44,45).
This post hoc analysis has a number
of limitations. First, the LEADER trial was
not specifically designed to assess the
risk of gallbladder- and biliary tract–
related events with liraglutide. Second,
the finding that cholecystectomy was
performed for similar proportions of
liraglutide-treated and placebo-treated
patients who experienced gallbladder-
or biliary tract–related events should be
interpreted with caution due to potential
differences between these patients.
Third, performing multiple comparisons
within a study can increase the proba-
bility of obtaining a false-positive result
(46), and no adjustment for multiple
statistical comparisons was made in
this analysis. Fourth, LEADER was con-
ducted in a population of patients at high
risk of CV disease, which may limit the
generalizability of these findings to the
wider population of patients with type 2
diabetes. Additionally, with respect to
gallstone disease event reporting, only
acute events were required to be re-
ported in the trial, so the number of
gallbladder stones was likely underesti-
mated. In other studies of populations
with diabetes, the reported prevalence
of gallstones, at 18%, was much higher
than reported here for LEADER (,2.45%)
(47,48) (Table 3). Further studies are
required to confirm the increase in gall-
bladder- or biliary tract–related events
and cholecystectomy with liraglutide and
to investigate the relevant mechanisms.
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